Dr Emily Sammons
BSc, MBChB, MSc
MRC PHRU Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit of the University of Oxford. She has particular research interests in diabetic eye disease and age-related macular degeneration. Alongside this she works on two large randomised controlled trials: ASCEND and REVEAL. ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes. REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease. Emily has background experience of working in General Medicine and a MSc in Public Health.
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
The Effects of Anacetrapib on Occlusive Vascular Events During Post-Trial Follow-Up of the REVEAL Randomized Trial
Sammons E. and Grp REVEALSC., (2019), CIRCULATION, 140, E971 - E971
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1529 - 1539
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1540 - 1550
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group None. et al, (2017), N Engl J Med, 377, 1217 - 1227